News for OPKO Health, Inc. (0KCS.L)

OPKO Health Inc's diversified healthcare portfolio positions it for growth in multiple medical markets.Strategic partnerships and proprietary technologies bols

Diagnostic Segment Revenue: $103.1 million for Q4 2024, compared to $124.2 million for Q4 2023.Pharmaceutical Segment Revenue: $80.5 million for Q4 2024, compa

Feb 27, 2025 / 09:30PM GMTOperator Good day. And welcome to the OPKO Health fourth quarter 2024 Financial Results Conference Call. All participants will be in a

OPKO Health, Inc. (NASDAQ:OPK) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

On February 27, 2025, OPKO Health Inc (OPK) released its financial results for the fourth quarter and full year ending December 31, 2024. The company highlighte

**media[552870]**

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a look at where OPKO Health, Inc.

Friday's Insider Activity: Top Buys and Sells in US Stocks Revealed

Wednesday's Insider Activity: Top Buys and Sells in US Stocks

**media[511049]**

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The ...

We recently published a list of 11 Best NASDAQ Penny Stocks To Buy Right Now. In this article, we are going to look at where OPKO Health, Inc.

Opko health CEO Phillip Frost buys $159k in common stock

**media[471487]**

MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) announced today that management will be participating in the Piper Sandler 36th Annual Healt

**media[460661]**

As per Fortune Business Insights’ report, the Esoteric Testing Market share sector attained a worth of USD 22.21 billion in 2022. Forecasts indicate a promising path, foreseeing a Compound Annual…

Entera Bio shares hold Buy rating on OXM study success